Objectives: Non-muscle-invasive bladder cancer is characterized by a high recurrence rate after primary transurethral resection. In case of bacillus Calmette-Guérin-refractory neoplasms, cystectomy is the gold standard. In this study the effects of thermochemotherapy with mitomycin C were evaluated in high-risk bladder cancer nonresponders to previous therapy. Patients and Methods: Between January 2006 and December 2009, 30 patients were enrolled with recurrent stage carcinoma in situ, Ta and T1, grade G1 to G3 non-muscle-invasive bladder cancer refractory to chemotherapy or immunotherapy and so becoming suitable for radical cystectomy. All patients underwent endovesical thermochemotherapy: 16 patients underwent a prophylactic scheme and 14 patients underwent an ablative scheme. Results: All the patients completed the study. The mean follow-up for all the patients enrolled was 14 months. Thirteen of 30 patients (43.30%) were disease free and 17 patients (56.70%) had recurrence. In the prophylactic group, 7 of 16 patients (43.75%) were disease free and 9 patients (46.25%) had tumor recurrence; no progression was observed. In the ablative group, 3 patients (17, 64%) had progression to muscle-invasive disease. Side effects were generally mild. Conclusions: Thermochemotherapy could be considered an additional tool in patients refractory to intravesical therapies before considering early cystectomy.

Keywords:
Non-muscle-invasive bladder cancer, Mitomycin C, Thermochemotherapy
1.
Kiemeney LA, Witjes JA, Heijbroek AL, Debruyne FM: Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;4:150–160.
2.
Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001;25:219–278.
3.
Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, et al: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156:1934–1940.
4.
Herr HW: Transurethral resection and intravesical therapy of superficial bladder tumors. Urol Clin North Am 1991;18:525–528.
5.
Melekos MD, Moutzouris GD: Intravesical therapy of superficial bladder cancer. Curr Pharm Des 2000;6:345–359.
6.
Bohle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90–95.
7.
Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964–1970.
8.
Witjes JA: Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006;49:790–797.
9.
Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L: Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superWcial bladder cancer: a single-center study. Urology 2003;61:338–341.
10.
Di Stasi SM, Giannantoni A, Giurioli A et al: Sequential BCG and electromotive mitomycin versus BCG alone for high risk superficial bladder cancer: a randomized controlled trial. Lancet Oncol 2006;7:43–51.
11.
Paroni R, Salonia A, Lev A, et al: Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52:273–278.
12.
Colombo R, Da Pazzo LF, Lev A, et al: Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996;155:1227–1232.
13.
Colombo R, Pozzo LFD, Salonia A, et al: Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–4276.
14.
Gofrit ON, Sahpiro A, Pode D, et al: Combined local bladder hyperthermia and intravesiscal chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63:466–471.
15.
Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C: EAU Recommendations 2001. ‘Guidelines on bladder cancer’. Prog Urol 2002;12:1161–1163.
16.
Yates DR, Rouprêt M: Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. BJU Int 2010;106:162–167.
17.
Freeman JA, Esrig D, Stein JP, et al: Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76:833–839.
18.
Cookson MS, Herr HW, Zhang ZF: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62–67.
19.
Herr HW, Sogani PC: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296–1299.
20.
Kondylis FI, Demirci S, Ladaga L, et al: Outcomes after intravesical bacillus Calmette-Guérin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol 2000;163:1120–1123.
21.
Knowles MA: What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001;54:215–221.
22.
Chopin DK, Gattegno B: Superficial bladder tumors. Eur Urol 2002;42:533–541.
23.
Kulkarni JN, Gupta R: Recurrence and progression in stage T1G3 bladder tumour with intravesical bacilli Calmette-Guérin (Danish 1331 strain). BJU Int 2002;90:554–557.
24.
Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P: Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996;155:1227–1232.
25.
Colombo R, Da Pozzo LF, Salonia A, et al: Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–4276.
26.
Gofrit ON, Shapiro A, Pode D, et al: Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63:466–471.
27.
van der Heijden AG, Kiemeney LA, Gofrit ON, et al: Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65–71.
28.
Colombo R, Lev A, Da Pozzo LF, et al: A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 1995;153:959–963.
29.
Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D: Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 2011;107:1685.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.